Nurix Therapeutics, Inc. NRIX Bexobrutideg (NX-5948) — R&D

Similar metrics at other companies

BCRXBCX17725 — Research and Development Expense (Excluding Acquired in Process Cost)

$1.91M-22.4%

EXELR&D

$199.92M-5.8%

AXSMR&D

$52.68M+17.6%

BMYR&D

$2.65B+17.4%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

ROIVBrepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$14.34M+9.7%

Questions, answered.

What is Nurix Therapeutics, Inc.'s bexobrutideg (NX-5948) — R&D?

Nurix Therapeutics, Inc. (NRIX) reported bexobrutideg (NX-5948) — R&D of $23.97M in Q4 2025.

How has Nurix Therapeutics, Inc.'s bexobrutideg (NX-5948) — R&D changed year-over-year?

Nurix Therapeutics, Inc.'s bexobrutideg (NX-5948) — R&D increased by 52.5% year-over-year, from $15.72M to $23.97M.

What does bexobrutideg (NX-5948) — R&D mean?

This metric represents the total direct operating expenses allocated to the research, clinical development, and pre-commercialization activities for a specific therapeutic candidate. It captures the investment intensity required to advance a drug through clinical trials and regulatory milestones. Monitoring this spend provides insight into the company's capital allocation strategy and the prioritization of its pipeline assets.